PRCTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
PROCEPT BioRobotics Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$18.28+0.71 (+4.04%)
Close on Oct 19, 2026
- Market cap
- $1.04B
- P/E (TTM)
- –
- Dividend yield
- –
PROCEPT BioRobotics Corp revenue by segment
By business segment
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $83.42M | $72.02M | $66.59M | $73.91M | $69.59M | $60.29M | $60.39M | $52.22M | $47.67M | $40.20M | $40.27M | $32.33M | 88.3% | +19.9% |
| Outside the United States | $11.08M | $11.11M | – | – | $9.60M | $8.87M | – | – | – | – | – | – | 11.7% | +15.4% |
| Outside of U.S. | – | – | – | $9.42M | $9.60M | $8.87M | $7.85M | $6.16M | $5.69M | $4.34M | $3.31M | $2.78M | – | – |
From the segment and revenue-disaggregation notes of PROCEPT BioRobotics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.